Davis Polk advised the sales agent on the offering. ImmunityBio, Inc. executed an at-the-market offering of its common stock for up to an aggregate amount of $500 million....
You must be a Standard 1 Year member to access this content.
Conyers and Davis Polk & Wardwell is advising Roivant Sciences Ltd., in its business combination by merger of a subsidiary with Montes Archimedes Acquisition Corp. (MAAC)...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vaccitech on the deal, while Davis Polk advised the representatives of the several underwriters. Vaccitech (Nasdaq: VACC) announced its initial public offering...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the representatives of the several underwriters in the offering. NeuroPace, Inc. executed its initial public offering of 6,900,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the representatives of the several underwriters in the offering. Akoya Biosciences, Inc. executed its $151.3 million initial public offering of 7,567,000 shares of common...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the representatives of the several purchasers in offering. Ionis Pharmaceuticals, Inc. executed its offering of an aggregate principal amount of $632.5 million of its...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the joint book-running managers in the offering. The $646.9 million secondary offering of 20,700,000 shares of common stock of Maravai LifeSciences Holdings, Inc....
You must be a Standard 1 Year member to access this content.
Davis Polk advised Jefferies, the sales agent, in the transaction. Beam Therapeutics Inc. executed the at-the-market offering of shares of its common stock for up to a...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Bridgepoint Capital on the deal. Bridgepoint Capital executed its acquisition of Sun World International. Financial terms of the transaction were not disclosed. Bridgepoint...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the joint book-running managers in the offering. Solid Biosciences Inc. executed the $143.75 million public offering of common stock. The common stock is listed...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the joint book-running managers and representatives of the several underwriters in the offering. Nurix Therapeutics, Inc. completed its follow-on offering of 5,175,000 shares...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the joint book-running managers in the offering. Adamas Pharmaceuticals, Inc. executed its $59 million follow-on offering of 14,375,000 shares of common stock, which included...
You must be a Standard 1 Year member to access this content.
